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Summary
Background: Although there is substantial interest in the use of newer biomarkers
to identify patients with chronic heart failure (CHF), recently few investigations
have evaluated the incremental usefulness of multiple conventional biomarkers.
Combination of several biomarkers simultaneously could enhance risk stratiﬁcation
in CHF.
Methods and results: We analyzed 7 biomarkers (brain natriuretic peptide, uric acid,
sodium, hemoglobin, creatinine, creatinine clearance, high-sensitivity C-reactive
protein), which were known as established prognostic markers for CHF, in 154 con-
secutive CHF patients, and patients were prospectively followed with endpoints of
cardiac death or re-hospitalization. When there was an abnormal value, we scored
it for one point to calculate multimarker score. Patients were categorized into 3
strata according to multimarker score. There were 83 cardiac events during the
follow-up period. A Cox proportional hazard model showed that patients in the high
stratum were associated with the highest risk of cardiac events among the 3 strata.
Kaplan—Meier analysis revealed that patients in the high stratum had a signiﬁcantly
higher cardiac event rate compared with lower strata.
Conclusion: The combination of conventional biomarkers could potentially improve
the risk stratiﬁcation of CHF patients for the prediction of cardiac events with low
cost and wide availability.
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Table 1 Clinical and laboratory characteristics of
154 patients with chronic heart failure.
All chronic heart
failure patients
(n = 154)
Age (years) 71± 12
Gender (male/female) 62/92
NYHA functional class (III/IV) 113/41
Hypertension 87 (56%)
Diabetes mellitus 40 (26%)
Hyperlipidemia 28 (18%)
Smoking 28 (18%)
Etiology of chronic heart failure
Dilated cardiomyopathy 52 (34%)
Ischemic heart disease 34 (22%)
Valvular heart disease 33 (21%)
Hypertensive heart disease 20 (13%)
Others 15 (10%)
Laboratory markers
Creatinine (mg/dl) 1.15± 0.86
Hemoglobin (g/dl) 12.0± 2.2
Sodium (mmol/L) 139.2± 3.8
Uric acid (mg/dl) 6.9± 2.4
BNP (pg/ml) 1019± 1140
hs-CRP (mg/dl) 0.46± 0.35
Creatinine clearance (ml/min) 44.5± 30.8
Multimarker score 4.27± 1.44
Echocardiography
LVEDD (mm) 56± 11
LVEF (%) 42± 19
Medications at discharge
ACE inhibitors and/or ARBs 108 (70%)
-Blockers 48 (31%)
Calcium channel blockers 26 (17%)
Spironolactone 51 (33%)
Loop diuretics 119 (77%)
Digoxin 55 (36%)
Statins 17 (11%)
NYHA, New York Heart Association; BNP, brain natriuretic
peptide; hs-CRP, high-sensitivity C-reactive protein; LVEDD,
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Introduction
Chronic heart failure (CHF) still represents the
major cause of death and hospitalization and has
a poor prognosis despite the signiﬁcant reduction
in mortality achieved in clinical trials [1—3]. The
prognostic evaluation of CHF patients involves a
complex assessment of multiple interacting vari-
ables. There is currently no simple clinical criterion
or score for predicting early outcome and iden-
tifying patients who require such caution. New
York Heart Association (NYHA) functional classi-
ﬁcation and several tests including chest X-ray,
echocardiography, radionuclide ventriculography,
cardiopulmonary exercise test, and hemodynamic
measurements, while helping to estimate the
degree of CHF, are subject to interobserver vari-
ations in interpretation. Therefore, the ability to
identify CHF patients at higher risk for adverse
outcomes has led to optimize therapeutic interven-
tions and improve the ominous prognosis [4].
Although there has been substantial interest
in the use of newer biomarkers for identiﬁcation
of CHF patients, risk assessment, and preven-
tion of cardiac events recently, few investigations
have evaluated the incremental usefulness of mul-
tiple conventional biomarkers. Measurement of
several biomarkers simultaneously could enhance
risk stratiﬁcation. Previous studies demonstrated
that elevated levels of brain natriuretic peptide
(BNP) [5], uric acid [6], and high-sensitivity C-
reactive protein (hs-CRP) [7], and decreased levels
of sodium [8] and hemoglobin [9], and renal
insufﬁciency [10] were associated independently
with increased risk of cardiac events in patients
with CHF. Importantly, each of these markers
assesses different pathophysiological mechanisms.
We hypothesized that simultaneous assessment of
these biomarkers will provide complimentary infor-
mation and enable clinicians to stratify risk more
effectively among CHF patients. We therefore eval-
uated the combination of 7 biomarkers (BNP, uric
acid, hs-CRP, sodium, hemoglobin, creatinine, cre-
atinine clearance) for predicting cardiac events in
154 consecutive patients hospitalized for CHF from
various etiologies during a mean follow-up period
of 526± 313 days.
MethodsStudy population
Between November 2001 and September 2007, we
prospectively studied 154 consecutive CHF patients
(62 men and 92 women, mean age 71± 12 years,
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>left ventricular dimension at end-diastole; LVEF, left ventric-
ular ejection fraction; ACE, angiotensin-converting enzyme;
ARB, angiotensin II receptor blocker.
ange 37—93 years) who had been admitted to
he Yamagata University Hospital for the treat-
ent of worsening CHF. The diagnosis of CHF was
ade by two senior cardiologists using the generally
ccepted Framingham criteria. Baseline charac-
eristics of the population are shown in Table 1.
xclusion criteria in this study were patients with
linical or electrocardiographic evidence sugges-
ive of acute coronary syndrome within 3 months
rior to admission, those with renal insufﬁciency
haracterized by a serum creatinine concentration
1.5mg/dl, and those with active hepatic dis-
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fultiple biomarkers in CHF
ase, active pulmonary disease, and degenerative
isease of the muscles. Patients who underwent
ercutaneous coronary intervention or coronary
rtery bypass graft within 3 months prior to admis-
ion were also excluded. Informed consent was
btained from all patients before participation in
his study, and the protocol was approved by the
uman Investigations Committee of our institution.
Blood samples were obtained at admission from
ll patients. The optimal cut-off values for 7
iomarkers were determined as those with the
argest sum of sensitivity plus speciﬁcity on each of
he receiver operating characteristic (ROC) curves.
hen there was an abnormal value, we scored
t for one point to calculate multimarker score.
atients were categorized into 3 strata according to
ultimarker score. Transthoracic echocardiography
as performed by experienced echocardiologists
ithout knowledge of the biochemical data using
n ultrasound instrument (Hewlett Packard SONOS
500 and 7500) equipped with a sector transducer
carrier frequency of 2.5 or 3.75MHz) within 1
eek of admission. Demographics and clinical data,
ncluding age, sex, and NYHA functional class at
dmission, were collected from hospital medical
ecords and patient interviews. Physicians were
ept blind to the results of the biochemical mark-
rs, and optimal medical therapy was administered
ndependently based on improvement in symptoms,
hysical examination ﬁndings, and pulmonary con-
estion on chest X-ray [11]. Diuretics were given
n ﬂexible dosages on the basis of body weight
nd daily diuresis. Spironolactone was administered
s 25 or 50mg/day. Angiotensin-converting enzyme
ACE) inhibitors, angiotensin II receptor blockers
ARBs), and -blockers were gradually increased to
he maximum dosage possible. The discharge was
ecided by two senior cardiologists using clinical
xamination, electrocardiogram, and chest X-ray
lm. The etiologies of CHF were dilated cardiomy-
pathy in 52 patients, ischemic heart disease in
4 patients, valvular heart disease in 33 patients,
nd hypertensive heart disease in 20 patients. The
iagnosis of dilated cardiomyopathy was based on
he deﬁnition of the WHO/ISFC task force [12]. The
iagnoses of hypertension, diabetes, and hyper-
ipidemia were obtained from medical records or
atient history of currently or previously received
edical therapy.
ndpoints and follow-upatients were prospectively followed-up and no
atients were lost to follow-up (mean follow-up
26± 313 days) after discharge from the Yamagata
niversity Hospital. The endpoints were (1) cardiac
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eath, deﬁned as death from worsening CHF or sud-
en cardiac death, and (2) worsening CHF requiring
eadmission. Sudden cardiac death was deﬁned as
eath without deﬁnite premonitory symptoms or
igns and was established by the attending physi-
ian. A review of medical records and follow-up
elephone interviews were conducted by senior
ardiologists to survey cardiac events, who were
linded to blood examination data. Cardiac events
ere adjudicated using electrocardiograms, chest
-ray reports, autopsy reports, death certiﬁcates,
nd witness statements.
tatistical analysis
esults are presented as mean± standard deviation
S.D.) for continuous variables and as the per-
entage of total patients for categorical variables.
he independent samples t-test or Mann—Whitney
est and chi-square test were used for comparisons
f continuous and categorical variables, respec-
ively. A Cox proportional hazard analysis was
erformed to evaluate the associations between
ardiac events and blood measurements. The car-
iac event-free curve was computed according to
he Kaplan—Meier method and compared by the
og-rank test. All p-values reported are two-sided,
nd a p-value < 0.05 was considered signiﬁcant. Sta-
istical analysis was performed with a standard
tatistical program package (StatView, version 5.0,
AS Institute Inc, Cary, NC, USA).
esults
he mean age of study subjects was 71± 12 years
ld. As shown in Table 1, 62 patients were men,
1 were in NYHA functional class IV, and 34 had
schemic heart disease. Mean multimarker score
as 4.27± 1.44.
ssociations with subsequent clinical
utcomes
here were 9 noncardiac deaths (3 cerebral infarc-
ion, 2 pneumonia, 2 lung cancer, 1 septic shock,
nd 1 suicide) and 83 cardiac events, including
3 cardiac deaths (5 in-hospital deaths) and 40
eadmissions for worsening heart failure during the
ollow-up period. The causes of cardiac death were
orsening CHF in 34 patients, fatal acute myocar-
ial infarction in 3 patients, and sudden cardiac
eath in 6 patients.
As shown in Table 2, patients with cardiac events
ere older, and had a higher multimarker score
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Table 2 Comparisons of clinical characteristics between patients with and without cardiac events.
Event free (n = 71) Cardiac events (n = 83) p-Value
Age (years) 68± 15 74± 10 0.0100
Gender (male/female) 29/42 33/50 0.8911
NYHA functional class (III/IV) 54/17 59/24 0.4856
Hypertension 43 (61%) 44 (53%) 0.3456
Diabetes mellitus 21 (30%) 19 (23%) 0.3461
Hyperlipidemia 10 (14%) 18 (22%) 0.2193
Current smoking 12 (17%) 16 (19%) 0.6270
Etiology of chronic heart failure
Dilated cardiomyopathy 27 (38%) 25 (30%)
Ischemic heart disease 13 (18%) 21 (25%)
Valvular heart disease 18 (25%) 15 (18%)
Hypertensive heart disease 6 (9%) 14 (17%)
Others 7 (10%) 8 (10%) 0.2951
Laboratory markers
Creatinine (mg/dl) 1.04± 0.64 1.25± 1.01 0.0436
Hemoglobin (g/dl) 12.9± 2.4 11.9± 2.2 0.0328
Sodium (mmol/L) 140.7± 2.6 138.2± 4.4 0.0008
Uric acid (mg/dl) 6.4± 1.9 7.2± 2.7 0.0254
BNP (pg/ml) 604± 1156 1032± 1134 <0.0001
hs-CRP (mg/dl) 0.33± 0.30 0.57± 0.34 0.0094
Creatinine clearance (ml/min) 56.8± 38.5 35.2± 19.3 0.0031
Multimarker score 3.85± 1.32 4.63± 1.45 0.0007
Echocardiography
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aLVEDD (mm) 55± 9
LVEF (%) 39± 18
Abbreviations as in Table 1.
compared with those without cardiac events. Fur-
thermore, as reported in previous studies [5—10],
patients with cardiac events showed renal dys-
function, anemia, hyponatremia, hyperuricemia,
and higher levels of BNP and hs-CRP compared
with those without cardiac events. Other parame-
ters including gender, NYHA functional class, and
numbers of patients with hypertension, diabetes
mellitus, hyperlipidemia, or currently smoking
were not signiﬁcantly different between patients
with and without cardiac events. In addition, there
was no difference in etiology of heart failure, left
ventricular end-diastolic diameter (LVEDD), and left
ventricular ejection fraction (LVEF).
Strata of multimarker score in CHF patients
The optimal cut-off values for 7 biomarkers were
determined as those with the largest sum of sensi-
tivity plus speciﬁcity on each of the ROC curves,
respectively (Fig. 1). When there was an abnor-
mal value, we scored it for one point to calculate
multimarker score. Patients were categorized into
3 strata according to multimarker score: low stra-
tum (multimarker score 0—3, n = 48), intermediate
stratum (multimarker score 4, n = 40), and high
R
P
t56± 11 0.6403
43± 18 0.2741
tratum (multimarker score 5—7, n = 66). Table 3
ummarizes the comparisons of the clinical char-
cteristics of the 3 strata. Patients in the high
tratum were older, had more severe NYHA func-
ional class, and higher rate of use of loop diuretics
ompared with lower strata. Furthermore, patients
n the high stratum had signiﬁcantly higher rates
f re-hospitalization and cardiac deaths than those
n the lower strata (Fig. 2). Average periods of
ollow-up days for the 3 strata were 817± 632 (low
tratum), 696± 586 (intermediate stratum), and
44± 492 (high stratum) days. The period was sig-
iﬁcantly shorter in the high stratum comparedwith
ower strata (p < 0.01). Whereas, other parameters
ncluding gender, etiology of heart failure, LVEDD,
nd LVEF were not signiﬁcantly different among the
strata. In addition, there was no difference in
he numbers of patients who had hypertension, dia-
etes mellitus, hyperlipidemia, or were currently
moking, and rate of use of ACE inhibitors, ARBs,
nd -blockers at discharge among the 3 strata.isk stratiﬁcation by the stratum analysis
rognostic results by the univariate Cox propor-
ional hazard analysis to predict cardiac events are
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Figure 1 Receiver operating characteristic (ROC) curve an
hs-CRP, high-sensitivity C-reactive protein; and Ccr, creatinin
shown in Fig. 3. The univariate Cox proportional
hazard analysis showed that risk of total cardiac
events (Fig. 3A) and cardiac deaths (Fig. 3B) were
signiﬁcantly higher in patients in the high stratum
compared with low stratum patients. In addi-
tion, patients in the high stratum were at higher
risk of total cardiac events (hazard ratio 1.934,
Figure 2 Cardiac mortality and cardiac events among
the 3 strata. Patients in the high stratum had higher rates
of re-hospitalization and cardiac deaths compared with
lower strata. **p < 0.001 by chi-square test.
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e clearance.
= 0.0144) and cardiac death (hazard ratio 1.393,
= 0.0313) compared with intermediate-stratum
atients. The hazard ratios of total cardiac events
Fig. 4A) and cardiac deaths (Fig. 4B) adjusted for
ge and sex were signiﬁcantly higher in patients
n the high stratum compared with low stratum
atients.
We performed univariate and multivariate Cox
roportional hazard regression analyses of predict-
ng cardiac events among multimarker score, age,
YHA functional class, and LVEF (Table 4). In the
nivariate Cox proportional hazard regression anal-
sis, multimarker score and age were signiﬁcantly
ssociated with cardiac events. Furthermore, only
ultimarker score was an independent predictor
f cardiac events among these variables by the
ultivariate Cox proportional hazard regression
nalysis.
Kaplan—Meier analysis demonstrated that
atients in the high stratum had a signiﬁcantly
igher total cardiac events rate (Fig. 5A) and
ardiac death rate (Fig. 5B) compared with lower
trata. One- and 2-year total cardiac event rates
ere 14.6% and 29.2% in low stratum, 27.5% and
7.5% in intermediate stratum, and 51.5% and
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Table 3 Comparisons of clinical characteristics among the 3 strata in chronic heart failure patients.
Low stratum (n = 48) Intermediate stratum (n = 40) High stratum (n = 66)
Age (years) 68± 14 70± 12 74± 10**##
Gender (male/female) 23/25 14/26 25/41
NYHA functional class (III/IV) 39/9 28/12 46/20$$
Hypertension 26 (54%) 24 (60%) 37 (56%)
Diabetes mellitus 18 (38%) 9 (23%) 13 (20%)
Hyperlipidemia 8 (17%) 6 (15%) 14 (21%)
Current smoking 9 (19%) 8 (20%) 11 (17%)
Etiology of chronic heart failure
Dilated cardiomyopathy 17 (35%) 12 (30%) 23 (35%)
Ischemic heart disease 13 (27%) 8 (20%) 13 (20%)
Valvular heart disease 4 (8%) 12 (30%) 17 (26%)
Hypertensive heart disease 6 (13%) 4 (10%) 10 (15%)
Others 8 (17%) 4 (10%) 3 (4%)
Laboratory markers
Creatinine (mg/dl) 0.76± 0.23 1.08± 0.67* 1.48± 1.10*##
Hemoglobin (g/dl) 12.7± 2.1 12.8± 2.0* 10.9± 2.0**##
Sodium (mmol/L) 141.1± 2.6 139.6± 3.9* 138.5± 4.1**#
Uric acid (mg/dl) 5.3± 1.8 6.9± 2.3** 7.9± 2.3**#
BNP (pg/ml) 566± 587 962± 844** 1380± 1447**#
hs-CRP (mg/dl) 0.34± 0.30 0.49± 0.40* 0.55± 0.32*#
Creatinine clearance (ml/min) 77.9± 44.2 50.3± 28.3** 32.4± 15.8**##
Multimarker score 2.60± 0.64 4.00± 0.00** 5.66± 0.73**##
Echocardiography
LVEDD (mm) 56± 10 55± 10 56± 11
LVEF (%) 39± 18 42± 18 42± 19
Medications at discharge
ACE inhibitors and/or ARBs 33 (69%) 30 (75%) 45 (68%)
-Blockers 12 (25%) 14 (35%) 22 (33%)
Calcium channel blockers 10 (21%) 4 (10%) 12 (18%)
Spironolactone 12 (25%) 19 (48%) 20 (30%)
Loop diuretics 31 (65%) 35 (88%) 53 (80%)#
Digoxin 16 (33%) 15 (38%) 24 (36%)
Statins 5 (10%) 4 (10%) 8 (12%)
*p < 0.05 and **p < 0.01 vs low, and #p < 0.05 and ##p < 0.01 vs intermediate. $p < 0.05 and $$p < 0.01 by chi-square test. Abbreviations
as in Table 1.
Figure 3 Hazard ratios to predict cardiac events among the 3 strata. The univariate Cox proportional hazard analysis
demonstrated that the high stratum was associated with the highest risk for total cardiac events (A) and cardiac deaths
(B) among the 3 strata. **p < 0.001 vs low stratum patients.
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Figure 4 Hazard ratios adjusted for age and sex by univariate Cox proportional hazard analysis. The high stratum was
associated with the highest risk for total cardiac events (A) and cardiac deaths (B) among the 3 strata. **p < 0.001 vs
low stratum patients.
Table 4 Univariate and multivariate analyses of predicting cardiac events.
Variable Hazard ratio 95% conﬁdence interval p-Value
Univariate analysis
Age (per 1 S.D. increase), (0.026, 12) 1.366 1.074—1.715 0.0111
NYHA functional class 1.305 0.810—1.117 0.0932
LVEF (per 1 S.D. increase), (0.011, 19) 0.812 0.625—1.039 0.0985
Multimarker score 1.764 1.342—2.320 <0.0001
Multivariate analysis
Age (per 1 S.D. increase), (0.019, 12) 1.256 0.964—1.657 0.0963
NYHA functional class 1.156 0.656—1.447 0.2159
LVEF (per 1 S.D. increase), (0.0008, 19) 0.985 0.649—1.122 0.2624
Multimarker score 1.689 1.239—2.304 0.0009
Abbreviations as in Table 1.
Figure 5 Kaplan—Meier analysis in chronic heart failure patients stratiﬁed into 3 strata based on multimarker score.
Patients in the high stratum had signiﬁcantly higher rates of total cardiac events (A) and cardiac deaths (B) compared
with lower strata.
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66.7% in high stratum, respectively. These results
suggest that in patients with high multimarker
score, prognosis is poor and intense follow-up
with chest-X ray, echocardiography, and blood
examination after discharge is recommended.
Discussion
In the present study, we showed that multimarker
score was higher in patients with cardiac events
than in those without cardiac events. The univari-
ate Cox proportional hazard analysis demonstrated
that patients in the high stratum were associated
with the highest risk for cardiac events compared
with lower strata. Only multimarker score was an
independent predictor of cardiac events among
age, NYHA functional class, and LVEF by the multi-
variate Cox proportional hazard regression analysis.
Furthermore, cardiac events occurred most fre-
quently in patients in the high stratum compared
with lower strata. These ﬁndings suggest that the
combination of multiple biomarkers could poten-
tially improve the risk stratiﬁcation of CHF patients
for the prediction of cardiac events.
Our results have clinical importance; incorporat-
ing this powerful risk prediction in the management
of patients with CHF may be potentially helpful
to improve their dismal prognosis. The suggested
multiple biomarkers reﬂecting different aspects of
interrelated pathophysiological processes of CHF
appear to be suitable to designate this high-risk
group of CHF patients. The 7 biomarkers in this
study are easy to measure in the routine exami-
nation, and can be used multiple times to follow
up patients without interobserver variability, and
are also appropriate in the emergency setting.
Therefore, it seems that this approach using mul-
tiple biomarkers is useful as one of the options for
risk stratiﬁcation and information of tailored treat-
ment, which includes more intense monitoring and
specialist care in CHF patients.
Many clinicians have encountered problems in
CHF patients. How will we identify and detect CHF
patients at an earlier stage? How do we predict CHF
patients with the greatest risk of cardiac events
or cardiac deaths? Shortness of breath, general
fatigue, and even edema do not necessarily indicate
the presence of CHF in a case. Nevertheless, the
clinician must have a high index of suspicion that
the source of patients’ problems may be CHF and
must assess whether patients have volume overload
and cardiac dysfunction. It seems that measure-
ment of these 7 markers may aid in the diagnosis
and assessment of CHF.T. Niizeki et al.
There was no difference in rate of use of
CE inhibitors, ARBs, and -blockers at discharge
mong the 3 strata. Multimarker score identiﬁed
HF patients who are at increased risk of car-
iac events and who may warrant more aggressive
herapy. It is important that we perform thera-
eutic intervention in prospective clinical trials
o improve prognosis of severe CHF patients in
he future. In addition, patients with preserved
jection fraction were included in this study.
e will analyze the difference in multimarker
core between patients with preserved ejection
raction and systolic heart failure in the future.
ardiac events increased with advancing multi-
arker score. Because echocardiography is subject
o interobserver variations in interpretation, it
eems this multimarker approach is a simple and
asy method to estimate severity and prognosis of
HF for many clinicians.
We selected 7 biomarkers on the basis of previous
xperimental and clinical studies. We acknowledge
ther biomarkers not tested in this study, such as
roponin T or heart-type fatty acid binding protein
markers for ongoing myocardial damage) [13—15],
ystatin C (a new marker for renal function) [16],
nd inﬂammatory [17] and oxidative stress mark-
rs [18]. Improvement in biomarker strategies may
epend on the discovery of new biomarkers.
onclusions
ur ﬁndings suggest that this simple multimarker
pproach demonstrates the potential to assist clin-
cians in predicting prognosis of CHF patients with
ow cost and wide availability. Future study is
eeded to show whether this multimarker approach
llows clinicians to improve management and prog-
osis in CHF patients.
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his study was supported in part by a grant-in-
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